Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Daiichi Sankyo and Amplimmune Announce Strategic Alliance to Develop AMP-110 Therapy for Autoimmune Disease
Provides for AMP-110 program acquisition by Daiichi Sankyo following "Proof of Concept"

TOKYO and GAITHERSBURG, Maryland, Jan. 7, 2013 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd. (hereafter, Daiichi Sankyo) and Amplimmune, Inc. (hereafter, Amplimmune) announced today that they have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein).  The collaboration will focus on development of AMP-110, a potential immune modulation therapy for autoimmune diseases.  This proprietary, first-in-class biologic works by blocking inflammatory T cell differentiation. The parties expect to initiate a Phase 1 clinical study for the compound for the treatment of an autoimmune disease indication in the first half of 2013.

Under the terms of the agreement, Daiichi Sankyo will pay Amplimmune an undisclosed option fee and provide more than $50 million to reimburse past and planned research and development costs for AMP-110 including funding for future development through a Phase 2 (Proof of Concept Study, hereafter, POC study).  Amplimmune also will be eligible to receive additional program milestone payments during the collaboration period.  Through the POC study, Daiichi Sankyo will have an exclusive option to acquire the AMP-110 program.

Under the terms of the agreement, Amplimmune will be responsible for manufacturing clinical supplies, regulatory filings and conducting clinical trials through a POC study in autoimmunity.  Amplimmune and Daiichi Sankyo expect to collaborate on research to further elucidate the characteristic of AMP-110 and to identify potential biomarkers to predict patient response to AMP-110.  If Daiichi Sankyo exercises its exclusive option to acquire the AMP-110 program, then following such acquisition, Daiichi Sankyo will be solely responsible for all future development, manufacturing and commercialization. 

"This collaboration strengthens our commitment to working with partners that are at the forefront of science," said Glenn Gormley, MD, PhD, global head of R&D, senior executive officer of Daiichi Sankyo.  "Immune modulation therapy is one of the exciting areas of autoimmune disease research that has the potential to meet an unmet medical need.  As a Global Pharma Innovator, identifying and meeting unmet medical needs is an important part of Daiichi Sankyo's mission. We are excited to start with the first trial."

"We are very pleased to be collaborating with Daiichi Sankyo on AMP-110," said Michael S. Richman, Amplimmune's President and Chief Executive Officer.   Richman continued, "This unique transaction allows Amplimmune to collaborate with an important and well-respected partner and positions the program for an acquisition that will provide significant value for both Daiichi Sankyo and our shareholders."

About B7-H4 and AMP-110

The B7-H4 pathway is believed to play a key role in maintaining tolerance and controlling inflammation.  B7-H4, first identified by Amplimmune scientific founder Dr. Lieping Chen, inhibits T-cell mediated inflammatory reactions. AMP-110, an Fc fusion of the extracellular domain of B7-H4, has been specifically designed to mimic the natural ability of B7-H4 to induce a co-inhibitory pathway that reduces inflammatory T cells known to contribute to autoimmune disease. Published preclinical data demonstrate the potency of AMP-110 to modulate autoimmune disease in a number of animal disease models. Given the fundamental nature of the B7-H4 pathway in balancing immune responses and preventing potential deleterious immune activation, AMP-110 has the potential to treat multiple autoimmune/inflammatory disease indications.

About Amplimmune, Inc.

Founded in 2007 and headquartered in Gaithersburg, MD, Amplimmune is focused on developing novel co-stimulatory/co-inhibitory molecules that rebalance the immune system and are intended for treating cancer, autoimmune disease, infectious disease, and transplantation. With its strong product-based focus, Amplimmune has rapidly developed three biologic product candidates: AMP-224 is in Phase 1b trials in cancer in collaboration with GlaxoSmithKline; AMP-110 for autoimmune diseases in partnership with Daiichi Sankyo; and AMP-514 for cancer. Working closely with its collaborators, Amplimmune is expanding its technology base in the area of immune co-stimulatory/co-inhibitory molecules and has assembled a large foundation of reagents, models, know-how, and intellectual property to further develop its product pipeline as well as to discover novel biomarkers, ligands, and receptors. The company is funded by InterWest Partners and The Wellcome Trust. For more information, please visit www.amplimmune.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

SOURCE Amplimmune

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT or...
Leysin American School is an exclusive, private boarding school located in Leysin, Switzerland. Leysin selected an OpenStack-powered, private cloud as a service to manage multiple applications and provide development environments for students across the institution. Seeking to m...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy...
Technology is enabling a new approach to collecting and using data. This approach, commonly referred to as the "Internet of Things" (IoT), enables businesses to use real-time data from all sorts of things including machines, devices and sensors to make better decisions, improve c...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation o...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE